Clinical Trial Update: STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE

View source ↗

Summary

Observational study evaluating erlotinib as second-line treatment in patients with squamous cell non-small cell lung cancer and wild-type EGFR; the trial status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Grupo Gallego de Cancer de Pulmon | Conditions: Carcinoma, Squamous Cell | Status: UNKNOWN